BRAF genotypes are often assayed in colon cancer, either by immunohistochemistry or other molecular assays as activating BRAF mutations are also a relative contraindication to EGFR targeted therapy [12], and BRAF status may play an additional role in Lynch syndrome screening [13]. Here, BRAF is linked to malignant colon neoplasm.